MAZE — Maze Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1842295 ·
Last close
$24.27
Market Cap
$1.34B
52W High
$53.65
52W Low
$22.71
ADV30
498,935
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,000,000 | — | -26,553,000 | -24,208,000 | 419,710,000 | 198,766,000 | 78,009,000 |
| Dec 2025 | 0 | — | -38,059,000 | -34,568,000 | 397,127,000 | 189,247,000 | 42,161,000 |
| Sep 2025 | 0 | — | -32,965,000 | -30,087,000 | 422,058,000 | 316,773,000 | 42,622,000 |
| Jun 2025 | 0 | — | -36,474,000 | -33,679,000 | 303,519,000 | 264,541,000 | 41,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-121,537,000
Investing CF
$-164,388,000
Financing CF
$190,316,000
CapEx
$-588,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.53
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-513,755,000
Inventory
—
Receivables
$20,000,000
ST Investments
$153,616,000
EBIT TTM
$-130,840,000
Pretax Income TTM
$-122,542,000
Interest Exp TTM
$866,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-131,888,000
Free Cash Flow
$-81,703,128
Enterprise Value
$1,052,070,464
Total Cash
$352,382,016
Total Debt
$61,223,000
Shares Out
55,345,261
Trailing EPS
$-2.35
Book Value
$6.93
ROE
-38.7%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -142,899,000 | -131,120,000 | 397,127,000 | 42,161,000 | — | -111,940,000 |
| Dec 2024 | 167,500,000 | 57,586,000 | 52,231,000 | 240,542,000 | 551,725,000 | — | 75,954,000 |
| Dec 2023 | 0 | -98,551,000 | -100,415,000 | 71,504,000 | 445,352,000 | — | -86,827,000 |
| Dec 2022 | 0 | -111,026,000 | -114,940,000 | 149,957,000 | 432,416,000 | — | -99,203,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.31
Max Pain — expiry 2026-11-20
max pain strike: $30.00 · spot: $23.86 · call oi: 626 · put oi: 634
Expected Move to 2026-11-20:
±$8.55
(35.83%) —
implied range
$15.31 –
$32.41
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.32B | $4.24 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.37B | $93.51 | — |
| IMTX | Immatics N.V. | $1.29B | $9.43 | — |
| VIR | Vir Biotechnology, Inc. | $1.45B | $8.61 | — |
| IMCR | Immunocore Holdings plc | $1.46B | $28.63 | — |
News headlines (Yahoo Finance, 1h cache)
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk
2026-06-13 19:10 · Yahoo
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
2026-06-08 03:44 · Yahoo
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
2026-06-05 19:00 · Yahoo
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
2026-05-27 11:03 · Yahoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
2026-05-17 19:13 · Yahoo
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts
2026-05-17 14:37 · Yahoo
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 21:15 · Yahoo
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-12 20:01 · Yahoo
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness
2026-05-12 02:10 · Yahoo
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
2026-05-07 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.